Document is current
Any future updates will be listed below
-
Authors
Bourgeois, Wallace
Rice, Hannah E.
Wenge, Daniela V. https://orcid.org/0000-0002-0064-9104
Perner, Florian https://orcid.org/0000-0003-1010-3321
Yue, Hong
Regalado, Brandon D.
Wan, George
Schroeder, Jan C. https://orcid.org/0000-0001-7000-4427
Sommerschield, Alba
Hatton, Charlie https://orcid.org/0000-0001-9903-4291
Singh, Shivendra
Singh, Sweta
Bijpuria, Shipra
McKeever, Brian M.
Miller, William H.
Safer, Jordan F. https://orcid.org/0009-0008-6007-7591
Iqbal, Sumaiya https://orcid.org/0000-0001-7700-4374
Perry, Jennifer A. https://orcid.org/0009-0003-2636-0952
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Doench, John G. https://orcid.org/0000-0002-3707-9889
McGeehan, Gerard M.
Cutler, Jevon A. https://orcid.org/0000-0002-3402-4292
Armstrong, Scott A. https://orcid.org/0000-0002-9099-4728
-
Funding
Funding for this research was provided by:
V Foundation for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NIH 5 P30 CA06516)
U.S. Department of Health & Human Services | National Institutes of Health (CA206963)
U.S. Department of Health & Human Services | National Institutes of Health (CA066996)
U.S. Department of Health & Human Services | National Institutes of Health (CA259273)
St. Jude Children's Research Hospital (Chromatin Collaborative award)
Damon Runyon Cancer Research Foundation
Deutsche Forschungsgemeinschaft (511811315)
Deutsche Forschungsgemeinschaft (PE 3217/4-1, PN: 517204983)
Else Kröner-Fresenius-Stiftung (2021-EKEA.111)
- License Information
-
More Information
Article History
Received: 28 March 2025
Accepted: 21 April 2026
First Online: 9 May 2026
Competing interests
: F.P. received travel support from Syndax Pharmaceuticals and CHARM Therapeutics. E.S.F. is an advisor and equity holder of Civetta Therapeutics, Proximity Therapeutics, Ajax Therapeutics, Neomorph Inc (also board of directors), Avilar Therapeutics, Stelexis Biosciences, Anvia Therapeutics (also board of directors) and Photys Therapeutics, equity holder in Lighthorse therapeutics and a consultant to Astellas, Sanofi, Novartis, Deerfield, and EcoR1 capital. The Fischer laboratory receives or has received research funding from Novartis, Deerfield, Ajax, Interline, and Astellas. J.A.C. reports consultant and advisory role for Sumitomo Dainippon Pharmaceuticals. S.A.A. has been a consultant and/or shareholder for Neomorph, C4 Therapeutics, Accent Therapeutics, Hyku Therapeutics, Stelexis BioSciences, and the Novartis Cancer Program. S.A.A. has received research support from Janssen and Syndax. S.A.A. is an inventor on a patent related to Menin inhibition WO/2017/132398A1. The remaining authors declare no competing interests.
